{
    "nct_id": "NCT06562114",
    "title": "A Phase 1, Safety, Tolerability, Single-ascending Dose, Multiple-ascending Dose, Food Effect, and Pharmacokinetic Study of TML-6 in Healthy Volunteers",
    "status": "RECRUITING",
    "last_update_time": "2024-08-15",
    "description_brief": "The purpose of this study is to evaluate the safety, tolerability, single-ascending dose (SAD), multiple-ascending dose (MAD), food effect, and pharmacokinetic (PK) Study of TML-6.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "TML-6 (synthetic curcumin analog, also referenced as ASC-6)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial title and description indicate a Phase 1 SAD/MAD/PK study of TML-6 in healthy volunteers (early safety/pharmacokinetics). Independent sources describe TML-6 as a synthetic curcumin analog and an oral small molecule with multi\u2011target actions relevant to Alzheimer\u2019s pathology \u2014 autolysosome/autophagy activation, Nrf2 (anti\u2011oxidative) activation, anti\u2011amyloid effects (\u03b2\u2011amyloid reduction/clearance), and anti\u2011inflammatory (NF\u2011\u03baB inhibition). \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: Extracted key details \u2014 drug name TML-6 (ASC\u20116), drug type = small molecule/curcumin analog, intended effects = reduce amyloid accumulation and modulate aging/autophagy pathways (disease\u2011modifying mechanisms). Clinical history/supporting documents report IND approval and initiation of a Phase 1 trial and subsequent Phase 2 planning based on Phase 1 safety/PK findings. \ue200cite\ue202turn0search7\ue202turn0search1\ue201",
        "Reflect: Given the drug is a small molecule designed to target Alzheimer\u2019s pathology (amyloid, autophagy/lysosomal pathway, oxidative/inflammatory pathways), it matches the definition of a \"disease\u2011targeted small molecule\" rather than a biologic, purely symptomatic cognitive enhancer, or a neuropsychiatric\u2011symptoms treatment. Preclinical and early clinical summaries support disease\u2011targeting intent. (Example preclinical efficacy and combination studies in AD mouse models also show A\u03b2 reduction with TML\u20116.) \ue200cite\ue202turn0search6\ue202turn0search3\ue201",
        "Web search results used: PR Newswire/press releases reporting IND approval and Phase 1/Phase 2 plans for TML\u20116 (Merry Life/MLB). \ue200cite\ue202turn0search7\ue202turn0search0\ue201",
        "PubMed publications describing TML\u20116 as a curcumin analog with multi\u2011targeted mechanisms (autophagy activation, Nrf2 activation, reduction of A\u03b2; used in AD animal models). \ue200cite\ue202turn0search3\ue202turn0search6\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The investigational drug TML-6 (aka ASC\u20116) is described in the literature and company releases as a synthetic curcumin analog with multiple disease\u2011modifying mechanisms relevant to AD \u2014 activation of Nrf2 (antioxidant), inhibition of mTOR with autophagy/autolysosome activation (proteostasis), reduction of A\u03b2/APP production and enhancement of A\u03b2 clearance (amyloid pathway), suppression of NF\u2011\u03baB (anti\u2011inflammatory), and upregulation of ApoE. These multi\u2011pathway actions are reported in preclinical publications and company trial announcements, indicating the intervention targets several CADRO categories simultaneously (amyloid, inflammation, oxidative stress, proteostasis, ApoE). \ue200cite\ue202turn1search3\ue202turn1search5\ue201",
        "Act: Extracted key details \u2014 drug name: TML\u20116 (ASC\u20116); drug type: oral small molecule / synthetic curcumin analog; reported mechanisms: Nrf2 activation (oxidative stress), mTOR inhibition/autophagy activation (proteostasis/proteinopathies), reduction of A\u03b2 and APP (amyloid), NF\u2011\u03baB inhibition (inflammation), ApoE upregulation (lipid/ApoE pathway). Because the described mechanisms span multiple CADRO categories rather than a single specific target, I assign: R) Multi-target. Supporting sources: the preclinical PubMed/PMC article and combination/efficacy study, and company press releases describing IND/Phase 1 and Phase 2 plans. \ue200cite\ue202turn1search3\ue202turn1search1\ue202turn0search3\ue202turn0search0\ue201",
        "Reflect: The multi\u2011mechanistic profile described in peer\u2011reviewed preclinical studies (improved behavior, reduced A\u03b2, Nrf2/mTOR/NF\u2011\u03baB/ApoE effects) plus company statements about multi\u2011target strategy and clinical progression justify the 'Multi\u2011target' CADRO classification rather than assigning a single pathway category (e.g., only Amyloid or only Inflammation). If future trial materials specify a single dominant molecular target, reclassification could be considered, but based on current evidence the most specific correct CADRO label is R) Multi\u2011target. \ue200cite\ue202turn1search3\ue202turn0search0\ue201",
        "Web search results cited (selected): (1) Preclinical peer\u2011reviewed study showing TML\u20116 biological effects (Nrf2, mTOR/autophagy, APP/A\u03b2 suppression, ApoE upregulation) and efficacy in AD mouse models. \ue200cite\ue202turn1search3\ue201 (2) Combination study showing additive effects of anti\u2011A\u03b2 antibody plus TML\u20116 in APP/PS1 mice (reduced A\u03b2, improved behavior, enhanced microglial phagocytosis). \ue200cite\ue202turn1search1\ue201 (3) PR Newswire: IND approval and Phase 1 SAD/MAD/PK study initiation (company announcement). \ue200cite\ue202turn0search3\ue201 (4) PR Newswire / company release announcing Phase II development and describing multi\u2011mechanistic/autolysosome focus. \ue200cite\ue202turn0search0\ue201 (5) MDPI / review of mechanistic implications from preclinical data. \ue200cite\ue202turn1search5\ue201"
    ]
}